🇺🇸 FDA
Pipeline program

SELPERCATINIB, SELPERCATINIB

LOXO-RET-17001

Phase 2 small_molecule active

Quick answer

SELPERCATINIB, SELPERCATINIB for Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood. is a Phase 2 program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
Ology Bioservices Ireland LTD
Indication
Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials